TTC30A: A Protein Exploring Potential Therapies for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: TTC30A

NCBI ID: G92104

TTC30A

TTC30A: A Protein Exploring Potential Therapies for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Tetratricopeptide repeat domain 30A (TTC30A) is a protein that is expressed in various tissues and cells in the human body. It is characterized by the repeated sequence of the amino acid leucine in the protein sequence. This repeated sequence is unique among proteins and is identified by the use of two domain names, TTC30A1 and TTC30A2.

The TTC30A1 protein is a 120 amino acid protein that is expressed in the brain, heart, liver, and kidneys. It is involved in a variety of cellular processes, including cell signaling, protein synthesis, and stress response. The TTC30A2 protein is a 194 amino acid protein that is mainly expressed in the liver and pancreas. It is involved in the regulation of inflammation and immune response.

Both TTC30A1 and TTC30A2 have been implicated in a variety of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. The repeated sequence of leucine in the protein sequence is thought to be the major contributor to the protein's unique structure and function.

One of the potential drug targets for TTC30A is the use of small molecules to inhibit the activity of the protein. This approach is being developed as a potential treatment for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting TTC30A is the use of antibodies to selectively bind to the protein and enhance its sensitivity to inhibitors. This approach is being used to develop diagnostic tests for a variety of diseases, including cancer and neurodegenerative diseases.

In addition to its potential as a drug target and diagnostic tool, TTC30A is also being studied for its potential role in the development of certain diseases. For example, studies have suggested that TTC30A may be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Overall, TTC30A is a protein that is being studied for its potential role in a variety of diseases and conditions. The repeated sequence of leucine in the protein sequence is thought to be the major contributor to its unique structure and function. While more research is needed, the potential of TTC30A as a drug target and diagnostic tool is being actively explored.

Protein Name: Tetratricopeptide Repeat Domain 30A

Functions: Required for polyglutamylation of axonemal tubulin. Plays a role in anterograde intraflagellar transport (IFT), the process by which cilia precursors are transported from the base of the cilium to the site of their incorporation at the tip

The "TTC30A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC30A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets